Drug intelligence / Profile preview

technetium tc 94m sestamibi

Development stage
Phase 2
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Technetium Tc 94m sestamibi is a radioconjugate consisting of the synthetic molecule sestamibi—an isonitrile compound—labeled with the positron-emitting isotope technetium-94m. Sestamibi itself is a lipophilic cationic agent that accumulates in tissues with high mitochondrial content and negative membrane potentials. When labeled with technetium isotopes, it serves as a radiotracer for imaging applications. The mechanism of action involves passive diffusion into cells and electrostatic retention within mitochondria; however, the precise mechanism for tissue localization can vary by tissue type and has not been fully established. The primary use of technetium-labeled sestamibi compounds (such as those using other isotopes) includes myocardial perfusion imaging to detect coronary artery disease, parathyroid adenoma localization, and breast cancer work-up[7]. With the positron-emitting isotope Tc-94m specifically, it would be used in PET imaging contexts.

Other names
sestamibi (when labeled with Tc-94m)isonitrile complex of technetium-94mMIBI (when labeled with Tc-94m)

Beyond the preview

Go deeper on technetium tc 94m sestamibi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium tc 94m sestamibi.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call